anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatectomy is widely considered a potential treatment for hepatocellular carcinoma (HCC). Unfortunately, one-third of HCC patients have tumor recurrence within 2 years after surgery (early recurrence), accounting for more than 60% of all recurrence patients. Early recurrence is associated with a worse prognosis. Previous studies have shown that microvascular invasion (MVI) is one of the key factors for early recurrence and poor prognosis in patients with HCC after surgery. This paper reviews the latest literature and summarizes the predictors of MVI, the correlation between MVI and early recurrence, the identification of suspicious nodules or subclinical lesions, and the treatment strategies for MVI-positive HCC. The aim is to explore the management of patients with MVI-positive HCC.
The present invention relates to vital melon which is a first-generation seed obtained by hybridizing Cucumis melo var. makuwa Makino and Cucumis melo var. reticulatus, an anti-obesity composition including extract of the vital melon, a pharmaceutical composition for preventing or treating obesity containing the anti-obesity composition, and anti-obesity health functional food containing the anti-obesity composition. The vital melon which is a first-generation seed obtained by hybridizing Cucumis melo var. makuwa Makino and Cucumis melo var. reticulatus has excellent anti-obesity effect and excellent productive capacity due to larger flesh than conventional Cucumis melo var. makuwa Makino. Also, an extract extracted from the vital melon is safe by using a natural product and can be used for an anti-obesity pharmaceutical composition or anti-obesity health functional food on the basis of anti-obesity effect of the vital melon, thereby widely used in the pharmaceutical industry and health food industry.
Based on previous work, we will recruit up to 75 Care Partners and their 75 care recipients with dementia. This allows for 20% attrition. We will recruit participants from Alzheimer's Disease Research Centers (ADRCs) and other national locations.
In this control arm, older adults will have a typical forward walking training that mirror the lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min forward walking. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
The primary goal of this project is to investigate whether commercial cognitive remediation therapy improves cognitive functioning in college undergraduates. The secondary goal is to investigate neurophysiological, cognitive, and psychosocial mechanisms of change. The investigators will compare cognitive remediation therapy to computer games. The active control condition will allow the investigators to determine whether targeted cognitive training, as an adjunct to academic skills training provided by CSU TILT, provides significant improvement over computer games alone (which is also thought to provide some value as "brain training"). Participants who agree to enroll in the study will be randomized to one of two intervention arms: cognitive remediation (CR) or active control (AC). In the CR arm, participants will complete 20 hours of targeted cognitive training, in 30-min session, 5 days per week, over 8 weeks. The AC Arm will follow the same schedule, except that participants will complete video games (e.g., pong). All participants will repeat assessments at randomly determined midpoint, as well as after the 8 weeks of training have been completed.
Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.
The patients will receive nimodipine (60 mg/4 hours) orally or via nasogastric tube from the first day of admission, then after the diagnosis of vasospasm is confirmed, Triple H therapy (hypertension, hypervolemia and hemodilution) will be started. norepnnephrine (0.01-0.2ug/kg/min) to mentain main arterial blood pressure \>100mmhg and hypervolemia to maintain the CVP around 12---14 mmHg and hemodilution to maintain the haematocrit between 30% and 33%.
PURPOSE:To provide the titled composition for external use, effective remarkably to the remedy of chapped skin, spots, freckles, pimples, etc., by using OREN (rhizoma of Coptis japonica MAKINO var. dissecta NAKAI) which is an orally administrable crude drug, as an essential active component of a cosmetic for continuous use. CONSTITUTION:Powder of OREN used as an oral drug such as a digestive, a herb medicine, a crude drug preparation, etc., or its extract with water or aqueous alcohol (e.g. an aqueous extract obtained by extracting with 30% ethanol at 15-25 deg.C: 1pt. of the extract can be obtained from 5pts. of the OREN), is added to a cosmetic in an amount of >=0.005wt%, preferably about 2wt%. The compounded composition can be used in the form of cream, beauty wash, baby powder, soap, etc. by conventional method.
Reconstitute the 175 mg vial contents with 3.6 mL of 0.9% Sodium Chloride Injection, USP, to obtain a clear, colorless to yellowish solution (resultant concentration 50 mg per mL levoleucovorin). Reconstitution with a sodium chloride solution with preservatives (e.g., benzyl alcohol) has not been studied. Do not store reconstituted solution for more than 12 hours at room temperature. Protect from light.

Dilute reconstituted solution immediately (if possible), to concentrations of 0.5 mg/mL to 5 mg/mL in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Do not store the diluted reconstituted solution for more than 12 hours at room temperature. Protect from light.

Visually inspect the product for particulate matter and discoloration prior to administration. Discard if particulate matter or discoloration is observed.
Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the "W\&W" cohort and omit radical surgery, while those without cCR will receive radical surgery.
Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The select phytoestrogen formulations are therapeutically useful to both women and men for sustaining neurological health and preventing age-related cognitive decline and neurodegenerative disorders, such as AD. These are administered enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.
In preparing radio-active threads by impregnation with soluble radio-active salts, e.g. radium bromide, followed by treatment with precipitants for the radio-active substance, e.g. ammonium sulphate, the threads are afterwards washed in repeatedly renewed pure water until no radio-active compounds can be detected in the washing water; or the washing may be made more effective by removing radio-active material from the superficial layers of the fibre by treatment with a solvent, e.g. alkali carbonate, for the insoluble material.  This may be followed by washing with dilute acids, e.g. hydrochloric or sulphuric acids or dilute sulphate solutions.  The threads may be finally coated with rubber, resin, &c.
Nicotinamide adenine dinucleotide (NAD)+ serves as a crucial coenzyme in numerous essential biological reactions, and its cellular availability relies on the activity of the nicotinamide phosphoribosyltransferase (NAMPT)-catalyzed salvage pathway. Here we show that treatment with saturated fatty acids activates the NAD+ salvage pathway in hypothalamic astrocytes. Furthermore, inhibition of this pathway mitigates hypothalamic inflammation and attenuates the development of obesity in male mice fed a high-fat diet (HFD). Mechanistically, CD38 functions downstream of the NAD+ salvage pathway in hypothalamic astrocytes burdened with excess fat. The activation of the astrocytic NAMPT-NAD+-CD38 axis in response to fat overload induces proinflammatory responses in the hypothalamus. It also leads to aberrantly activated basal Ca2+ signals and compromised Ca2+ responses to metabolic hormones such as insulin, leptin, and glucagon-like peptide 1, ultimately resulting in dysfunctional hypothalamic astrocytes. Our findings highlight the significant contribution of the hypothalamic astrocytic NAD+ salvage pathway, along with its downstream CD38, to HFD-induced obesity.
All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
High-fat diet (HFD) has been linked to female infertility. However, the specific age at which HFD impacts ovarian function and the underlying mechanisms remain poorly understood. Here, we administered a HFD to female mice at various developmental stages: pre-puberty (4 weeks old), post-puberty (6 weeks old), young adult (9 weeks old), and middle age (32 weeks old). Our observations indicated that ovarian function was most significantly compromised when HFD was initiated at post-puberty. Consequently, post-puberty mice were chosen for further investigation. Through transplantation of fecal bacteria from the HFD mice to the mice on a normal diet, we confirmed that gut microbiota dysbiosis contributed to HFD-induced deteriorated fertility and disrupted estradiol synthesis. Utilizing untargeted and targeted metabolomics analyses, we identified L-saccharopine as a key metabolite, which was enriched in the feces, serum, and ovaries of HFD and HFD-FMT mice. Subsequent in vitro and in vivo experiments demonstrated that L-saccharopine disrupted mitochondrial homeostasis by impeding AMPKα/MFF-mediated mitochondrial fission. This disruption ultimately hindered estradiol synthesis and compromised oocyte quality. AICAR, an activator of AMPKα, ameliorated L-saccharopine induced mitochondrial damage in granulosa cells and oocytes, thereby enhancing E2 synthesis and improving oocyte quality. Collectively, our findings indicate that the accumulation of L-saccharopine may play a pivotal role in mediating HFD-induced ovarian dysfunction. This highlights the potential therapeutic benefits of targeting the gut microbiota-metabolite-ovary axis to address HFD-induced ovarian dysfunction.
PURPOSE:To obtain a bathing agent effective in eliminating body smell by mixing a dry-distillation extract of green tea to a bathing agent. CONSTITUTION:The objective bathing agent can be produced by mixing 1-5% of a dry-distillation extract of green tea extracted from tea leaves to a powdery bathing agent prepared e.g. by compounding a colorant, a perfume, etc., to borax and a carbonate (e.g. sodium carbonate). The dry-distillation extract of green tea is prepared by dry-distilling the whole leaves of green tea including the twig or dried coarse powder of the leaves and adding a proper amount of ethanol to the fraction distilled at 180-200 deg.C. The dry-distillation extract of green tea extracted from tea leaves has deodorizing effect effective in eliminating the body smell. Since the dry-distillation extract of green tea is a natural substance, there is no adverse effect on the skin in contact with the agent.
Febuxostat is a xanthine oxidase inhibitor. The active ingredient in febuxostat is 2-[3-cyano­-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, with a molecular weight of 316.37. The molecular formula is C16H16N2O3S. 

The chemical structure is:

Febuxostat is a white to off white color powder that is freely soluble in dimethylformamide; soluble in dimethylsulfoxide; sparingly soluble in ethanol; slightly soluble in methanol and acetonitrile; and practically insoluble in water. The melting range is 205°C to 208°C.

Febuxostat tablets for oral use contain the active ingredient, febuxostat, and are available in two dosage strengths, 40 mg and 80 mg. Inactive ingredients include ammonium hydroxide, colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide black, iron oxide yellow, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, propylene glycol, shellac and titanium dioxide.
Two-year studies were conducted in CD1 mice and Wistar rats to assess the carcinogenic potential of icatibant. No evidence of tumorigenicity was observed in mice and rats at icatibant subcutaneous doses up to 15 mg/kg/day (twice per week) and 6 mg/kg/day (daily), respectively (approximately 10-fold and 6-fold greater than the MRHD on an AUC basis, respectively).

Icatibant tested negative for genotoxicity in the in vitro Ames bacterial reverse mutation test, in vitro Chinese hamster bone marrow chromosome aberration assay, and in vivo mouse micronucleus test. 

Daily subcutaneous administration of icatibant to rats and dogs caused ovarian, uterine, and testicular atrophy/degeneration and adverse effects on the mammary and prostate glands. In rats, testicular atrophy, reduced prostate gland secretion, decreased testosterone levels and degenerate corpora lutea occurred at doses greater than or equal to 3 mg/kg (approximately 5-fold greater than the MRHD in males and 2-fold greater than the MRHD in females on an AUC basis) and a decrease in developing ovarian follicles, mammary gland masculinization, and uterine atrophy occurred at doses greater than or equal to 10 mg/kg (approximately 6-fold greater than MRHD in females on an AUC basis). In dogs, reduced sperm counts and uterine atrophy occurred at doses greater than or equal to 1 mg/kg (approximately 2-fold greater than the MRHD on an AUC basis). Atrophy of the testes and prostate with decreased testosterone levels, decreased ovary size and decreased number of developing follicles occurred at a dose of 10 mg/kg (approximately 30-fold greater than the MRHD in males and 15-fold greater than at the MRHD in females on an AUC basis).

In contrast to the effects of daily icatibant administration, toxicity to the ovary, uterus, testis, mammary gland, and prostate did not occur in dogs treated twice a week for 9 months. AUC exposures from a dose of 3 mg/kg in these dogs were 5- and 3-fold the MRHD exposures in men and women, respectively. Sperm counts and testosterone remained unaffected over the course of the study in male dogs dosed twice a week. 

Reproduction studies in male mice and rats with daily administration of icatibant found no effects on fertility or reproductive performance with intravenous doses up to 81 mg/kg (approximately 5-fold greater than the MRHD on a mg/m2 basis) or subcutaneous doses up to 10 mg/kg (approximately 11-fold greater than the MRHD on an AUC basis), respectively.
BACKGROUND: Corticobasal syndrome (CBS) is a neurodegeneration characterized by asymmetric parkinsonism, dystonia, myoclonus, and apraxia. In the early stage, CBS presents with asymmetric parkinsonism and cortical symptoms (apraxia and alien hand), and neuroimaging finding is often vague, making early clinical differentiation from idiopathic Parkinson disease (IPD) challenging. This study was performed to delineate the specific patterns of cortical hypoperfusion, dopamine transporter (DAT) uptake using dual-phase FP-CIT PET in discriminating between CBS and IPD at early stage.
PATIENTS AND METHODS: The study enrolled clinically diagnosed CBS (n = 11) and IPD (n = 22) patients (age and sex matched). All participants underwent dual-phase 18 F-FP-CIT PET, and regional SUV ratio (SUVR) was obtained by semiquantitative analysis. The early perfusion imaging and DAT imaging were compared between groups.
RESULTS: The regional SUVRs (early phase) of the frontal lobe, thalamus, cingulate, and caudate were significantly lower in patients with CBS, whereas the SUVR of occipital lobe was lower in the IPD group. The CBS group exhibited more prominent asymmetry than the IPD group, particularly in the perirolandic area, superior frontal gyrus, and anterior parietal lobe in early phase PET. Striatal DAT uptake (delayed phase) revealed that the caudate showed lower SUVR and prominent asymmetry in the CBS group, and the caudate-to-putamen ratio (CP ratio) was significantly lower in CBS patients ( P < 0.001). Among the parameters (early and delayed), the CP ratio in DAT exhibited the most powerful discriminative power from receiver operating characteristic curve comparison (area under curve = 0.983).
CONCLUSIONS: This study demonstrated that the dual-phase FP-CIT PET is useful in differentiating CBS and IPD in the early stage of the disease, and a lower CP ratio of DAT imaging is highly informative for distinguishing between corticobasal degeneration and IPD.
OBJECTIVE: To provide an update on the association between preoperative membranous urethral length (MUL) and postoperative urinary incontinence (UI) in men who undergo robot-assisted radical prostatectomy (RARP)/robot-assisted laparoscopic prostatectomy (RALP).
MATERIALS AND METHODS: Urinary incontinence is common after RARP/RALP, and early recovery of continence is one of the most important functional outcomes following surgery. MUL has been identified as a factor associated with continence recovery after RARP/RALP. A systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, using PubMed, Embase, and Scopus databases. Inclusion criteria were English language full journal articles authored within the last 5 years that assessed continence using the Expanded Prostate Cancer Index Composite. The Critical Appraisal Skills Programme tool for retrospective cohort studies was used to evaluate study quality. A random-effects meta-analysis was performed to pool odds ratios (ORs) from available studies relating to continence as a function of MUL. The Grading of Recommendations, Assessment, Development and Evaluations framework was used to synthesise evidence.
RESULTS: Six studies including 970 patients reported an association between MUL and continence at 12 months. Longer MUL was associated with reduced UI odds at 12 months after surgery (pooled OR 0.74, 95% confidence interval 0.68-0.87, P < 0.001). Significant methodological and statistical heterogeneity was encountered.
CONCLUSIONS: Preoperative MUL measured on magnetic resonance imaging (MRI) is significantly associated with postoperative continence in men undergoing RARP/RALP. We recommend consideration of MRI measurement of MUL prior to RARP/RALP to guide treatment decisions in this population.
The invention discloses a product for treating hemorrhoid. The product comprises the following raw material components: gizzard, chicken butt and tadpole. The invention also provides a method for producing a traditional Chinese medicine for treating the hemorrhoid. The method comprises the following steps of: chopping and mixing the gizzard, the chicken butt and the tadpole; wrapping the mixture by flour; and pouring vegetable oil into a pot and frying for eating. The product provided by the invention has the effects of dispelling melancholy, removing stasis, harmonizing channels, removing blood stasis, eliminating the hemorrhoid and effectively treating the hemorrhoid. The product of the invention has the advantages of low cost, simple processing, short treatment course, quick response and no toxic or side effect due to the used natural raw materials.
The new guidelines for pediatric immune thrombocytopenia (ITP) not only include changes to the name and staging of the disease, but also introduce the modified Buchanan's bleeding score for the assessment of bleeding symptoms. Treatments should aim to improve patients' health-related quality of life (HRQoL) based on a multidimensional assessment of not only platelet counts but also bleeding symptoms, as well as activity level, lifestyle, and access to healthcare. First-line therapy includes intravenous immunoglobulin therapy (IVIG) and short-term corticosteroids. Second-line therapy includes thrombopoietin receptor agonists, rituximab, and splenectomy. Many novel agents are also in development, with splenic-derived tyrosine kinase (Syk), Bruton's kinase (BTK), and fetal Fc receptor (FcRn) attracting attention as target molecules. Future developments in the treatment of pediatric ITP are eagerly awaited.
The present invention relates to a kind of glycosaminoglycan lyases and encoding gene and application. Is the amino acid sequence of glycosaminoglycan lyases as SEQ? ID? shown in NO.2; Is the nucleotide sequence of the encoding gene of glycosaminoglycan lyases as SEQ? ID? shown in NO.1; Glycosaminoglycan lyases prepared by the present invention is 110,000U/mg, is 45,000U/mg to the specific activity of chondroitin sulfate hyaluronic specific activity; Enzyme activity be known commercialization glycosaminoglycan lyases (as, CSaseABC, CSaseAC? I and II etc.) tens to hundreds of times, can be applicable to the field such as medicine and cosmetics, have broad application prospects.
Patients undergo FSRS over 30-90 minutes for 3 fractions on study. Additionally, patients undergo CT and MRI on study.
PROBLEM TO BE SOLVED: To provide a method for extraction by which an oleaginous substance in Ganoderma lucidum spores can be obtained in high yield in a good state. SOLUTION: This method for extracting the oleaginous substance from germination- activated Ganoderma spores or nongermination-activated Gaderma spores comprises (1) breaking the sporoderm with a mechanical means and (2) extracting the oleaginous substance from the sporoderm-broken spores using a method for superctitical fluid- carbon dioxide (SCF-CO2 ) extraction. The preferred supercritical conditions are 5-60 MPa supercritical pressure, 32-85 deg.C supercritical temperature and 5-80 kg/h flow capacity rate. The preferred SCF-CO2 extraction time is 0.5-6 h. The method for activating germination of the Ganoderma spores is carried out by (1) culturing the spores in a nutritional solution and inducing the germination and then (2) placing the spores in a sufficiently ventilated culture box at a constant temperature and humidity and activating the spores.  According to the method for extraction, the oleaginous substance in an amount of about 37% based on the spore weight is obtained and the resultant oleaginous substance is transparent and has a fragrance unique to the Ganoderma spores. There is no trace of deposit, solvent residue or oxidation in the oleaginous substance.